Document is current
Any future updates will be listed below
-
Authors
Fredericksen, R. J. http://orcid.org/0000-0003-3936-7048
Nance, R. M.
Whitney, B. M.
Harding, B. N.
Fitzsimmons, E.
Del Rio, C.
Eron, J.
Feaster, D. J.
Kalokhe, A. S.
Mathews, W. C.
Mayer, K. H.
Metsch, L. R.
Mugavero, M. J.
Potter, J.
O’Cleirigh, C.
Napravnik, S.
Rodriguez, B.
Ruderman, S.
JAC, Delaney
Crane, H. M.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (1R01DA032098-01, R01DA035280, 5U01DA037702)
National Institute of Allergy and Infectious Diseases (R24 AI067039, P30 AI027757, P30 AI027767)
- License Information
-
More Information
Article History
Received: 25 August 2020
Accepted: 24 September 2021
First Online: 9 October 2021
Declarations
:
: Human subject research approval was obtained via the each associated institution’s Institutional Review Boards. For the PACTO and RETAIN studies, approval was obtained via Miami University IRB. For sites within CNICS, approval was obtained from University of Washington, University of Alabama at Birmingham, and Fenway Community Health for CNICS; for remaining CNICS sites (Case Western Reserve University, University of North Carolina- Chapel Hill, University of California at San Diego), IPV measures are integrated into routine clinical care yielding de-identified data. Informed written consent was obtained by all study participants where applicable.
: Not applicable.
: None.
